Company Dossier · Health Care
Idexx Laboratories
- S&P 500
- Nasdaq-100
- Russell 1000
What Idexx Laboratories is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $4.55 billion, up 13% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.25 billion, up 60% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.12 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $1.22 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 4, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 15 outlook figures raised, 1 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 20, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $1.2 million on the open market.SEC Form 4
- 1,308 institutional managers reported a position at June 30, 2026 (−10 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 9 (10 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Idexx Laboratories is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Retrenching · Confident
Expanding ↔ Retrenching
Retrenching
- Capital spending43rd pct
- Debt raised—
- Buybacks vs capex3rd pct
- Hiring filings25th pct
- Deals and private raises49th pct
- Patent publications42nd pct
Confident ↔ Hedging
Confident
- Call sentiment56th pct
- Call confidence91st pct
- Guidance changes87th pct
- Risk factors added75th pct
- Insider open-market trades44th pct
- + Guidance changes
- + Call confidence
- + Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver8th pct
- Stress filings48th pct
Credit
How these are built →Idexx Laboratories's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$0.4B
- Due within a year $0.1B
- Longer term $0.3B
- Default point $0.3B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 6, 2026Patent
- Aug 18, 2026Patent
- Aug 11, 2026Patent
- Jul 28, 2026Patent
- Jun 16, 2026Patent
- May 15, 20268-KShareholder vote resultsItem 5.07
- Apr 3, 2026Trademark
- Mar 26, 20268-KDirector or officer changeItem 5.02
- Feb 20, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 13, 20268-KDirector or officer changeItem 5.02
- Jan 13, 20268-KDirector or officer changeItem 5.02
- Nov 13, 20258-KMaterial agreement signedItem 1.01
- Oct 7, 20258-KDirector or officer changeItem 5.02
- Jul 10, 20258-KDirector or officer changeItem 5.02
- May 9, 20258-KShareholder vote resultsItem 5.07
- Mar 28, 2025Trademark
- Mar 4, 2025Trademark
- Mar 4, 2025Trademark
- Feb 21, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 14, 20258-KDirector or officer changeItem 5.02
- Dec 12, 20248-KDirector or officer changeItem 5.02
- Nov 21, 20248-KDirector or officer changeItem 5.02
- Nov 12, 20248-KDirector or officer changeItem 5.02
- Nov 6, 20248-KMaterial agreement signedItem 1.01
- Feb 22, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Dexcom DXCM | $5.0B | $1.4B | Jun 30, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| Steris STE | $6.0B | $0.9B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |
| Globus Medical GMED | $3.1B | $0.8B | Jun 30, 2026 |
| Insulet Corporation PODD | $3.0B | $0.3B | Jun 30, 2026 |
| Revvity RVTY | $2.9B | $0.6B | Jul 5, 2026 |